Accessibility StatementSkip Navigation —Â Â Â Third Quarter Revenues of $394.2 Million — —Â Â Â GAAP Net Income of $82.8 Million and Diluted GAAP Earnings per Share of $0.49 — —Â Â Â Company Raises 2025 Financial Expectations — Revenues | (In millions) | Three Months Ended | Nine Months Ended | | | | | --- | --- | --- | --- | --- | --- | | | September 30, | September 30, | | | | | 2025 | 2024 | 2025 | 2024 | | | | Total Revenues | $ | 394.2 | $ | 378.1 $ 1,091.4 $ 1,127.6 | | | Total Proprietary Net Sales | ...

Core Insights - Alkermes plc is set to present detailed results from its Vibrance-1 phase 2 study on alixorexton for narcolepsy type 1 at the World Sleep Congress in Singapore from September 5-10, 2025, and during an investor webcast on September 8, 2025 [1][2][7] Company Overview - Alkermes plc is a mid-cap global biopharmaceutical company focused on developing innovative medicines in neuroscience, with a portfolio addressing various neurological disorders including narcolepsy and idiopathic hypersomnia [10] Study Details - The Vibrance-1 study is a phase 2, randomized, double-blind, placebo-controlled trial involving 92 participants, evaluating the safety and efficacy of alixorexton in adults with narcolepsy type 1 [8] - Participants were assigned to receive one of three doses of alixorexton (4 mg, 6 mg, or 8 mg) or placebo once daily for six weeks, with primary and secondary endpoints focusing on wakefulness and other narcolepsy symptoms [8] Presentation Highlights - Three oral presentations will cover the safety and efficacy of alixorexton, improvements in fatigue and cognitive function, and the study design for the Vibrance-3 study evaluating alixorexton in idiopathic hypersomnia [4][5][6] - The presentations will take place during the "Targeting the orexin pathway: Emerging pharmacotherapies for narcolepsy type 1" session on September 8, 2025 [4] Research Community Engagement - The World Sleep Congress will feature leading researchers and clinicians discussing new datasets on orexin 2 receptor agonists, highlighting the ongoing commitment to improving care for patients with hypersomnolence disorders [2][3]